Jeanette Lundin

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)

Jeanette Lundin, Eva Kimby, Magnus Björkholm et al. · Blood · 2002 · 496 citations · Full text

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome

Jeanette Lundin, Hans Hagberg, Roland Repp et al. · Blood · 2003 · 389 citations · Full text

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

Gunilla Enblad, Hans Hagberg, Martin Erlanson et al. · Blood · 2004 · 302 citations · Full text

CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.

Jeanette Lundin, Anders Österborg, G. Brittinger et al. · Journal of Clinical Oncology · 1998 · 258 citations

Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study

M Hedenus, G Birgegård, Per Näsman et al. · Leukemia · 2007 · 199 citations

Hematological Malignancy, Laboratory Hematology, Randomized Multicenter Study +8